دورية أكاديمية
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas
العنوان: | AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas |
---|---|
المؤلفون: | Bunse, LukasAff1, Aff2, Rupp, Anne-Kathleen, Poschke, IsabelAff1, Aff4, Bunse, TheresaAff1, Aff2, Lindner, KatharinaAff1, Aff5, Wick, AntjeAff6, Aff7, Blobner, Jens, Misch, Martin, Tabatabai, Ghazaleh, Glas, Martin, Schnell, Oliver, Gempt, Jens, Denk, Monika, Reifenberger, Guido, Bendszus, Martin, Wuchter, Patrick, Steinbach, Joachim P, Wick, WolfgangAff6, Aff7, Aff19, Platten, MichaelAff1, Aff2, Aff4, IDs4246602200184x_cor19 |
المصدر: | Neurological Research and Practice. 4(1) |
قاعدة البيانات: | Springer Nature Journals |
كن أول من يترك تعليقا!